Current and Emerging Antimicrobial Therapies for Respiratory Tract Infections in Children with Cystic Fibrosis

Emine ATAĞa , Zeynep Seda UYANb

aMaltepe University Faculty of Medicine, Division of Pediatric Pulmonology, İstanbul, Türkiye
bKoç University Faculty of Medicine, Division of Pediatric Pulmonology, İstanbul, Türkiye

ABSTRACT

Cystic fibrosis (CF) is a multisystem disease caused by Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene mutations. Dehydrated and thick airway secretions resulting from CFTR channel dysfunction predispose to respiratory tract infections in these patients. Respiratory tract infections are an important cause of morbidity and mortality in these patients. Therefore, it is crucial to identify respiratory infections and treat them appropriately. In this section, important pathogens that cause respiratory tract infections in children with CF and current treatment approaches for these infections will be reviewed.

Keywords: Child; cystic fibrosis; respiratory tract infections

Referanslar

  1. Blanchard AC, Waters VJ. Opportunistic pathogens in cystic fibrosis: epidemiology and pathogenesis of lung infection. J Pediatric Infect Dis Soc. 2022;7;11-3. [Crossref]
  2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918-51. [Crossref]
  3. Thornton CS, Parkins MD. Microbial epidemiology of the cystic fibrosis airways: past, present, and future. Semin Respir Crit Care Med. 2023;44(2):269-86. [Crossref]
  4. Zemanick ET, Hoffman LR. Cystic Fibrosis: Microbiology and Host Response. Pediatr Clin North Am. 2016;63(4):617-36. [Crossref]
  5. Wolter DJ, Onchiri FM, Emerson J, Precit MR, Lee M, McNamara S, et al. Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study. Lancet Respir Med. 2019;7(12):1027-38. [Crossref]
  6. Smyth AR, Rosenfeld M. Prophylactic antistaphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2017;4:CD001912. [Crossref]
  7. National Institute for Health and Care Excellence 2017. Cystic fibrosis: Diagnosis and management. Available at: (cited: October 5, 2023). [Link]
  8. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187:680-9. [Crossref]
  9. Clinical guidelines: Care of children with cystic fibrosis, 2023. (cited: october 5, 2023). [Link]
  10. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2021. (cited: October 10). [Link]
  11. Lee TWR. Eradication of early Pseudomonas infection in cystic fibrosis. Chronic Respiratory Disease. 2009;6(2):99-107. [Crossref]
  12. Lund-Palau H, Turnbull AR, Bush A, Bardin E, Cameron L, Soren O, et al. Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Rev Respir Med. 2016; 10(6):685-97. [Crossref]
  13. Mogayzel PJ, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, et al. Cystic Fibrosis Foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc. 2014;11(10):1640-50. [Crossref]
  14. Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153-78. [Crossref]
  15. Regan KH, Bhatt J. Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. 2019;4(4): CD009876. [Crossref]
  16. Sunman B, Emiralioglu N, Hazirolan G, Ademhan Tural D, Ozsezen B, Nayir Buyuksahin H, et al. Impact of Achromobacter spp. isolation on clinical outcomes in children with cystic fibrosis. Pediatr Pulmonol. 2022;57(3):658-66. [Crossref]
  17. Wang M, Ridderberg W, Hansen CR, Høiby N, Jensen-Fangel S, Olesen HV, et al. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. J Cyst Fibros. 2013;12(6):638-43. [Crossref]
  18. Richards CJ, Olivier KN. Nontuberculous mycobacteria in cystic fibrosis. Semin Respir Crit Care Med. 2019;40(6):737-50. [Crossref]
  19. UK Cystic Fibrosis Registry 2021 Annual Data Report. (cited: October 3). [Link]
  20. Floto RA, Olivier KN, Saiman L, et al; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016; 71(Suppl 1):i1-i22. [Crossref]
  21. Martiniano SL, Davidson RM, Nick JA. Nontuberculous mycobacteria in cystic fibrosis: Updates and the path forward. Pediatr Pulmonol. 2017;52(S48):S29-S36. [Crossref]
  22. Tracy MC, Moss RB. The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatr Pulmonol. 2018;53(S3):S75-S85. [Crossref]
  23. Schwarz C, Bouchara JP, Buzina W, et al. Organization of patient management and fungal epidemiology in cystic brosis. Mycopathologia. 2018;183:7-19. [Crossref]
  24. Magee LC, Louis M, Khan V, Micalo L, Chaudary N. Managing fungal infections in cystic fibrosis patients: challenges in clinical practice. Infect Drug Resist. 2021;22;14:1141-53. [Crossref]
  25. Lamoureux C, Guilloux CA, Beauruelle C, Jolivet-Gougeon A, Héry-Arnaud G. Anaerobes in cystic fibrosis patients' airways. Crit Rev Microbiol. 2019;45(1):103-17. [Crossref]
  26. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, et al. Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. Ann Am Thorac Soc. 2014;11(8):1298-306. [Crossref]
  27. Flight W, Jones A. The diagnosis and management of respiratory viral infections in cystic fibrosis. Expert Rev Respir Med. 2017;11(3):221-7. [Crossref]
  28. Billard L, Le Berre R, Pilorgé L, Payan C, Héry-Arnaud G, Vallet S. Viruses in cystic fibrosis patients' airways. Crit Rev Microbiol. 2017;43(6):690-708. [Crossref]
  29. Calver JF, Fabbri L, May J, Jenkins RG. COVID-19 in patients with chronic lung disease. Clin Chest Med. 2023;44(2):385-93. [Crossref]
  30. Brackenborough K, Ellis H, Flight WG. Respiratory viruses and cystic fibrosis. Semin Respir Crit Care Med. 2023;44(2):196-208. [Crossref]